Paris (France), Cambridge (Massachusetts, United States)), March 20, 2023, 8:00 a.m. CET – Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a biotechnology company specializing in the development of drugs intended to slow down the degenerative processes associated with aging, in particular severe respiratory failure in patients suffering from COVID-19, announces today that it will share the recent progress of its clinical project MYODA (development of BIO101 in Duchenne muscular dystrophy (DMD)) as well as the therapeutic potential of BIO101 in rare neuromuscular diseases at the MDA Clinical & Scientific Conference to be held in Dallas, Texas, March 19-22, 2023.
Biophytis will present the following poster: “BIO101 drug candidate for the treatment of rare neuromuscular diseases. Preclinical proofs of concept in DMD and SMA and clinical perspectives”.
Biophytis intends to start clinical development in non-ambulatory patients with Duchenne muscular dystrophy (DMD) in 2023 (MYODA program). With orphan drug designation already granted in the US and EU, Biophytis will meet with the FDA for a Type C meeting and the EMA for scientific advice, in the second quarter of 2023, to align with the strategy. clinical trial that will support the development of BIO101 in DMD.